Try our Advanced Search for more refined results
IN RE: Testosterone Replacement Therapy Products Liability Litigation
Case Number:
2545
Court:
Judicial Panel on Multidistrict Litigation
Nature of Suit:
Judge:
Firms
- Anapol Weiss
- Arnold & Porter
- Barrios Kingsdorf
- Beasley Allen
- Burg Simpson
- Davis & Crump
- DLA Piper
- Domengeaux Wright
- Douglas & London
- Foote Mielke
- Hendy Johnson
- Herman Herman & Katz
- Johnson Becker
- Kaiser Gornick
- Lanier Law Firm
- Levin Papantonio
- Levin Sedran
- Lockridge Grindal
- MacDonald Law Group LLC
- Meyers & Flowers
- Morelli Law Firm
- Morgan Lewis
- Morgan & Morgan
- Morrison Mahoney
- Myron M. Cherry & Associates
- NastLaw
- Peiffer Wolf
- Reed Smith
- Robins Cloud
- Ross Feller Casey
- Schlichter Bogard
- Seeger Weiss
- Shook Hardy
- Winston & Strawn
- Zoll & Kranz
-
June 29, 2018
Actavis Reaches Tentative Deal To Exit Testosterone MDL
Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products, according to an order filed Friday.
-
June 14, 2018
Plaintiffs Want AbbVie Fined $500K In Testosterone Row
Counsel for AndroGel users suing AbbVie Inc. in a multidistrict litigation over injuries allegedly caused by testosterone replacement therapy drugs asked an Illinois federal judge to slap the company with nearly $500,000 in sanctions Wednesday, claiming AbbVie misused a records-collecting process to challenge nearly 1,000 suits.
-
April 24, 2018
AbbVie Disputes $3M AndroGel Verdict In MDL Bellwether
AbbVie Inc. asked an Illinois federal court Monday to grant a new trial, enter a judgment against the patient who brought suit or overturn a $3.2 million verdict that found the drugmaker's testosterone replacement therapy AndroGel caused the patient's heart attack, saying the jury's finding was contradictory.
-
February 26, 2018
Judge Orders Redo In First AbbVie Testosterone MDL Trial
An Illinois federal judge has ordered a new trial in the first bellwether against AbbVie Inc. in the multidistrict litigation over testosterone replacement therapy products after finding that the jury likely misunderstood the issue of causation.
-
August 22, 2017
UHC Ignoring Subpoena In Testosterone MDL, Endo Says
UnitedHealthcare should hand over subpoenaed information about its dealings in testosterone replacement drugs if it wants to become part of a proposed class of insurers and third-party payors accusing drug companies of fraudulently marketing the drugs, Endo Pharmaceuticals Inc. told an Illinois federal court Monday.
-
December 22, 2016
Doctor In Testosterone Gel MDL Must Reveal Drug Co. Deals
A doctor in multidistrict litigation over the marketing of testosterone replacement drugs who plaintiffs say was one of the biggest proponents of the drugs' use for more conditions has to turn over records of payments he received from the drugs' manufacturers, an Illinois federal judge ruled Thursday.
-
August 30, 2016
Actavis Wants Conspiracy Claim Nixed In Testosterone MDL
Actavis on Monday asked an Illinois federal judge to reconsider letting Racketeer Influenced and Corrupt Organizations Act conspiracy charges stand in an insurer’s multidistrict litigation over fraudulent marketing for testosterone replacement drugs, arguing that the fact that Actavis entered into a promotion contract with co-defendant AbbVie Inc. doesn’t prove it knew AbbVie was allegedly engaged in illegal activity.
-
February 04, 2016
AbbVie, Others Escape Some Testosterone Therapy Claims
An Illinois federal judge on Thursday tossed most of a putative class action accusing AbbVie Inc. and other pharmaceutical companies of causing health insurers to pay for medically unnecessary uses of testosterone replacement therapy drugs via fraudulent marketing, but allowed the deficient claims to be amended.
-
March 03, 2015
FDA Slaps New Warnings On Testosterone Drugs
The U.S. Food and Drug Administration on Tuesday ordered AbbVie Inc., Eli Lilly & Co. and other manufacturers of testosterone replacement drugs to warn patients of serious cardiovascular risks and clarify approved uses, another big setback for the heavily marketed therapies.
-
May 01, 2014
Pfizer Says It Doesn't Belong In Testosterone Gel MDL
Pfizer Inc. argued Wednesday that it had no place in proposed multidistrict litigation targeting makers of prescription testosterone medications that allegedly caused men to suffer heart attacks and strokes, saying the four suits over its injectable treatment differed from the dozens of cases against manufacturers.